Read by QxMD icon Read

Lancet HIV

Kathleen R Page, Suzanne Dolwick Grieb, Karen Nieves-Lugo, Thespina Yamanis, Holly Taylor, Omar Martinez, Yoshiaki Yamasaki, Rupali Limaye, Wendy Davis, Chris Beyrer, María Cecilia Zea
In our work as clinicians, researchers, and immigrant rights advocates, we have noted increased anxiety about the possibility of deportation and disruptions in care among immigrants with HIV. Before the 2016 US elections, patients rarely asked about HIV treatment in their home countries. However, since the increase in anti-immigrant rhetoric and arrests by US Immigration and Customs Enforcement, patients have voiced concerns about the availability of HIV treatment in their home countries much more frequently...
July 6, 2018: Lancet HIV
Catriona Waitt, Nicola Low, Philippe Van de Perre, Fiona Lyons, Mona Loutfy, Karoline Aebi-Popp
Can the campaign Undetectable=Untransmittable (U=U), established for the sexual transmission of HIV, be applied to the transmission of HIV through breastfeeding? European AIDS Clinical Society and, to some extent, American guidelines now state that mothers with HIV who wish to breastfeed should be supported, with increased clinical and virological monitoring. This Viewpoint summarises existing evidence on transmission of HIV through breastfeeding, differences in HIV dynamics and viral load between breastmilk and plasma, and the effects of antiretroviral therapy on infants...
June 27, 2018: Lancet HIV
Heather Bailey, Rebecca Zash, Virginia Rasi, Claire Thorne
Almost 25 years since antiretroviral therapy (ART) was first shown to prevent mother-to-child transmission of HIV, 76% of pregnant women living with HIV (over 1 million women) receive ART annually. This number is the result of successes in universal ART scale-up in low-income and middle-income countries. Despite unprecedented ART-related benefits to maternal and child health, challenges remain related to ART adherence, retention in care, and unequal access to ART. Implementation research is ongoing to understand and to address obstacles that lead to loss to follow-up...
June 26, 2018: Lancet HIV
Jeremy Sugarman, Mark Barnes, Scott Rose, Kostyantyn Dumchev, Riza Sarasvita, Ha Tran Viet, Oleksandr Zeziulin, Hepa Susami, Vivian Go, Irving Hoffman, William C Miller
People who inject drugs with high-risk sharing practices have high rates of HIV transmission and face barriers to HIV care. Interventions to overcome these barriers are needed; however, stigmatisation of drug use and HIV infection leads to safety concerns during the planning and conduct of research on such interventions. In preparing to address concerns about safety and wellbeing of participants in an international research study, HIV Prevention Trials Network 074, we developed participant safety plans (PSPs) at each site to supplement local research ethics committee oversight, community engagement, and usual clinical trial procedures...
June 22, 2018: Lancet HIV
(no author information available yet)
No abstract text is available yet for this article.
June 22, 2018: Lancet HIV
(no author information available yet)
No abstract text is available yet for this article.
June 18, 2018: Lancet HIV
Eric S Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi, Catherine Creticos, Jürgen K Rockstroh, Jean-Michel Molina, Ellen Koenig, Ya-Pei Liu, Joseph Custodio, Kristen Andreatta, Hiba Graham, Andrew Cheng, Hal Martin, Erin Quirk
BACKGROUND: Switching from therapy based on a boosted protease inhibitor to bictegravir, emtricitabine, and tenofovir alafenamide could avoid drug interactions and unwanted side-effects in virologically suppressed adults with HIV-1 infection, while maintaining a high barrier to resistance and providing a simplified once-daily, single-tablet regimen. Here, we report 48 week results of a phase 3 study investigating this switch. METHODS: In this multicentre, randomised, open-label, active-controlled, non-inferiority, phase 3 trial, adults with HIV-1 infection were enrolled at 121 outpatient centres in ten countries...
June 15, 2018: Lancet HIV
Jean-Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans-Jürgen Stellbrink, Luis López-Cortés, Peter Ruane, Daniel Podzamczer, Cynthia Brinson, Joseph Custodio, Hui Liu, Kristen Andreatta, Hal Martin, Andrew Cheng, Erin Quirk
BACKGROUND: Bictegravir, co-formulated with emtricitabine and tenofovir alafenamide, has shown good efficacy and tolerability, and similar bone, renal, and lipid profiles to dolutegravir, abacavir, and lamivudine, in treatment-naive adults with HIV-1 infection, without development of treatment-emergent resistance. Here, we report 48-week results of a phase 3 study investigating switching to bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir, abacavir, and lamivudine in virologically suppressed adults with HIV-1 infection...
June 15, 2018: Lancet HIV
Marianne Harris
No abstract text is available yet for this article.
June 15, 2018: Lancet HIV
Sarit A Golub, Chibuzo U Enemchukwu
No abstract text is available yet for this article.
June 13, 2018: Lancet HIV
Brandon D L Marshall, William C Goedel, Maximilian R F King, Alyson Singleton, David P Durham, Philip A Chan, Jeffrey P Townsend, Alison P Galvani
BACKGROUND: Oral pre-exposure prophylaxis (PrEP) prevents HIV infection in men who have sex with men (MSM); however, adherence is an ongoing concern. Long-acting injectable PrEP is being tested in phase 3 trials and could address challenges associated with adherence. We examined the potential effectiveness of long-acting injectable PrEP compared with oral PrEP in MSM. METHODS: We used an agent-based model to simulate HIV transmission in a dynamic network of 11 245 MSM in Atlanta, GA, USA...
June 13, 2018: Lancet HIV
Dan H Barouch
No abstract text is available yet for this article.
June 8, 2018: Lancet HIV
Linda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, Fatima Laher, Georgia D Tomaras, Kristen W Cohen, Mary Allen, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Carter Bentley, Nicole Frahm, Daryl E Morris, Lynn Morris, Nonhlanhla N Mkhize, David C Montefiori, Marcella Sarzotti-Kelsoe, Shannon Grant, Chenchen Yu, Vijay L Mehra, Michael N Pensiero, Sanjay Phogat, Carlos A DiazGranados, Susan W Barnett, Niranjan Kanesa-Thasan, Marguerite Koutsoukos, Nelson L Michael, Merlin L Robb, James G Kublin, Peter B Gilbert, Lawrence Corey, Glenda E Gray, M Juliana McElrath
BACKGROUND: Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted to express HIV-1 antigens from strains circulating in South Africa, and the adjuvant was changed to increase immunogenicity. Furthermore, 12-month immunisation was added to improve durability. In the HIV Vaccine Trials Network (HVTN) 100 trial, we aimed to assess this new regionally adapted regimen for advancement to efficacy testing...
June 8, 2018: Lancet HIV
Nittaya Phanuphak, Praphan Phanuphak
No abstract text is available yet for this article.
June 6, 2018: Lancet HIV
Martin Holt, Toby Lea, Limin Mao, Johann Kolstee, Iryna Zablotska, Tim Duck, Brent Allan, Michael West, Evelyn Lee, Peter Hull, Andrew Grulich, John De Wit, Garrett Prestage
BACKGROUND: Pre-exposure prophylaxis (PrEP) has been rapidly rolled out in large, publicly funded implementation projects in Victoria and New South Wales, Australia. Using behavioural surveillance of gay and bisexual men, we analysed the uptake and effect of PrEP, particularly on condom use by gay and bisexual men not using PrEP. METHODS: We collected data from the Melbourne and Sydney Gay Community Periodic Surveys (GCPS), cross-sectional surveys of adult gay and bisexual men in Melbourne, VIC, and Sydney, NSW...
June 6, 2018: Lancet HIV
Jienchi Dorward, Richard Lessells, Paul K Drain, Kogieleum Naidoo, Tulio de Oliveira, Yogan Pillay, Salim S Abdool Karim, Nigel Garrett
A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled out in low-income and middle-income countries (LMICs). In studies from predominantly high-income settings, dolutegravir-based regimens had superior efficacy, tolerability, and durability compared with existing first-line regimens. However, several questions remain about the roll out of dolutegravir in LMICs, where most people with HIV are women of reproductive age, tuberculosis prevalence can be high, and access to viral load and HIV drug resistance testing is limited...
June 5, 2018: Lancet HIV
Praphan Phanuphak, Nittaya Phanuphak
No abstract text is available yet for this article.
May 31, 2018: Lancet HIV
Phunlerd Piyaraj, Frits van Griensven, Timothy H Holtz, Philip A Mock, Anchalee Varangrat, Wipas Wimonsate, Warunee Thienkrua, Jaray Tongtoyai, Atitaya McNamara, Wannee Chonwattana, Kenrad E Nelson
BACKGROUND: The finding of casual sex partners on the internet and methamphetamine use have been described as risk factors for HIV infection in men who have sex with men (MSM). However, the interplay between these factors has not been studied prospectively in one design. This study aims to determine the associations between finding casual sex partners on the internet and incident methamphetamine use and HIV infection. METHODS: In this observational cohort study of Thai MSM, we recruited Bangkok residents aged 18 years or older with a history of penetrative male-to-male sex in the past 6 months...
May 31, 2018: Lancet HIV
(no author information available yet)
No abstract text is available yet for this article.
May 29, 2018: Lancet HIV
Philippa Harris
No abstract text is available yet for this article.
June 2018: Lancet HIV
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"